CAMPERR
Recruiting
7,000 enrolled
VeRVe
Recruiting
500 enrolled
A Long-term Follow-up Study of Patients Who Received VOR33
Terminated
10 enrolled
Tempus Priority Study: A Pan-tumor Observational Study
Active not recruiting
1,000 enrolled
CARCML
Recruiting
240 enrolled
BELUGA
Recruiting
25,000 enrolled
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Recruiting
150 enrolled
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting
20,000 enrolled
OMNI
Terminated
3 enrolled
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
Completed
208 enrolled
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
Completed
1,769 enrolled
A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment
Completed
84 enrolled
Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt
Completed
173 enrolled
Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)
Completed
503 enrolled
PREDICARE
Completed
420 enrolled
PASS
Completed
101 enrolled
TRAFIC
Completed
130 enrolled 5 charts
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
Completed
173 enrolled
HOLA
Completed
5,443 enrolled
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity
Completed
15 enrolled
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients
Completed
801 enrolled
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Completed
500 enrolled